Dr Quentin M. Anstee is a Clinical Senior Lecturer in the Institute of Cellular Medicine. A practising clinician, he is also an Honorary Consultant Hepatologist in the Liver Unit at the Freeman Hospital, Newcastle.
Dr Anstee's primary research interest is the study of genetic modifiers of progressive liver disease. His translational research has extended from the bench to the bedside with particular focus on the pathogenesis and treatment of Non-Alcoholic Steatohepatitis (NAFLD/NASH) and the role of Coagulation in Hepatic Fibrosis. He is actively involved in ongoing clinical trials of new therapies for fatty liver disease and hepatic fibrosis.
Dr Anstee trained in medicine at University College London where he was awarded First Prize in Medicine in the final MB BS examination (The Philip Seth Belasco & Douglas Cree Prize, 1997).
His post-graduate specialist clinical training in Hepatology/Gastroenterology & General Medicine was undertaken at hospitals in North-West London. Prior to joining ICM, he worked as Clinical Lecturer in Medicine & Hepatology at Imperial College London and St Mary's Hospital from 2007-2010.
Dr Anstee's clinical practice is based in the Regional Liver Unit at the Freeman Hospital. He has expertise in the management of patients with a range of acute and chronic liver conditions including:
He has a particular sub-specialist interest in the management of non-alcoholic fatty liver disease and, together with Professor Chris Day, runs the regional fatty liver service. He also provides diagnostic and therapeautic Upper GI Endoscopy & Colonoscopy services at the Freeman Hospital and the Royal Victoria Infirmary, Newcastle.
Membership of Editorial Boards:
Peer Review Activity:
Invited Lectures at National & International Meetings:
Dr Anstee's primary research interest is the study of genetic modifiers of progressive liver disease. His translational research has extended from the bench to the bedside with particular focus on the pathogenesis and treatment of Non-Alcoholic Steatohepatitis (NAFLD/NASH) and the role of Coagulation in Hepatic Fibrosis. He has ongoing fruitful collaborations with both industrial and scientific partners at other UK and international liver units and is a member of the European Union FP7 funded Fatty Liver Inhibition of Progression 'FLIP' Consortium.
Dr Anstee's scientific research has employed gene-driven and phenotype‐driven ethyl-nitrosourea (ENU) mutagenesis screens and more traditional targeted genetic modification techniques to generate and study models of complex genetic disease traits including alcohol addiction, non-alcoholic steatohepatitis, drug induced liver injury (paracetamol toxicity and antibiotic related idiosyncratic drug reactions), primary biliary cirrhosis and liver fibrosis. His research is facilitated by his role as an Honorary Group Leader of the Liver Group at the MRC Mammalian Genetics Unit, MRC Harwell.
His research has led to an MRC Experimental Medicine funded clinical trial examining the efficacy of anticoagulation to slow graft fibrosis in hepatitis C infected liver transplant patients (WAFT-C) and studies of novel therapies in NAFLD/NASH including caspase inhibition and gut flora modulation (RiFL). He is a principal investigator in ongoing clinical trials of new therapies for fatty liver disease and hepatic fibrosis.
Dr Anstee is the recipient of a HEFCE Clinical Senior Lecturer Award. He has previously received an MRC Clinical Research Fellowship to study genetic modifiers of Non-Alcoholic Steatohepatitis (NASH) & Liver Fibrosis.
He has received research grant funding from sources including the MRC, Wellcome Trust, Academy of Medical Sciences and Imperial College NIHR Biomedical Research Centre.